50 Best Peptides
Designed to Feel
Bestseller by Peter Burchardt
Designed to Feel
Your anxiety, jealousy, and anger aren't broken — they're ancient software running in a world they weren't built for. This book is the missing manual.
“The most eye-opening book on emotions I've ever read.”
Get It on Amazon →Available in paperback & Kindle

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

Reviewed by the 50 Best Peptides Editorial Team
#8

Liraglutide

Weight ManagementVictozaSaxendaNN2211
⚪Anecdotal

Based primarily on community reports and observational data

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.

Purchase for Research

For laboratory and research purposes only. Not intended for human or animal consumption.

Buy Research Peptides

15% OFF

Use code 50Best at checkout

Share:

Overview

Liraglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1), functioning as a receptor agonist. It is primarily used for weight management and as a treatment for type 2 diabetes. The molecular structure of liraglutide includes a fatty acid side chain that allows it to bind to albumin, increasing its half-life and enabling once-daily dosing. Upon administration, liraglutide binds to the GLP-1 receptor, a member of the G protein-coupled receptor family, which enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety, all contributing to its weight management properties.

The clinical trial history of liraglutide is robust, with notable trials such as the SCALE Obesity and Prediabetes trial (PMID: 27345421) demonstrating its efficacy in weight management. Another pivotal trial, the LEADER trial (PMID: 27299850), assessed cardiovascular outcomes and confirmed the cardiovascular safety of liraglutide in patients with type 2 diabetes. These trials have established liraglutide not only as an effective weight loss agent but also as a cardiovascular-safe option for individuals with obesity and related comorbidities.

Pharmacokinetically, liraglutide exhibits a half-life of approximately 13 hours, making it suitable for once-daily dosing. It is predominantly metabolized by proteolytic cleavage and excretion occurs via the urine and feces. Its ability to maintain stable plasma concentrations with minimal peak-to-trough fluctuation is a significant advantage in the management of chronic conditions like obesity and type 2 diabetes.

In the current therapeutic landscape, liraglutide is marketed under the brand names Victoza and Saxenda. While Victoza is primarily aimed at glycemic control in type 2 diabetes, Saxenda is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. The dual role of liraglutide in managing both diabetes and obesity underlines its importance in addressing the obesity-diabetes continuum.

Looking to the future, research is focusing on exploring liraglutide's potential in other metabolic disorders and its long-term effects on weight maintenance. Studies are underway to evaluate its efficacy in combination therapies, exploring synergistic effects with other weight loss agents. Furthermore, ongoing research is assessing its role in non-alcoholic steatohepatitis (NASH) and polycystic ovary syndrome (PCOS), broadening its therapeutic potential.

## Key PubMed References 1. SCALE Obesity and Prediabetes trial: PMID: 27345421 2. LEADER trial: PMID: 27299850 3. Pharmacokinetics study: PMID: 22275440 4. Liraglutide for weight management: PMID: 25182100 5. Cardiovascular safety of liraglutide: PMID: 27299850

Research Uses & Applications

  • Weight management in adults with obesity
  • Glycemic control in type 2 diabetes
  • Potential treatment for non-alcoholic steatohepatitis (NASH)
  • Management of polycystic ovary syndrome (PCOS)
  • Cardiovascular risk reduction in type 2 diabetes patients
  • Adjunct therapy in combination with other weight loss agents
  • Investigation for use in adolescent obesity
  • Exploration in prediabetes management

Key Research Findings

  • SCALE Obesity and Prediabetes trial demonstrated significant weight loss in liraglutide users (PMID: 27345421, 2016)
  • LEADER trial confirmed cardiovascular safety in type 2 diabetes (PMID: 27299850, 2016)
  • Liraglutide showed improved glycemic control in type 2 diabetes patients (Journal of Clinical Endocrinology & Metabolism, 2013)
  • Enhanced satiety and reduced hunger observed in liraglutide treatment (Diabetes, Obesity and Metabolism, 2015)
  • Liraglutide reduced HbA1c levels significantly compared to placebo (Lancet, 2010)
  • SUSTAIN 6 trial reported reduced risk of nephropathy (PMID: 27939002, 2016)
  • Investigational studies show potential in reducing liver fat content in NASH (Hepatology, 2018)

Risks & Side Effects

  • Increased risk of pancreatitis, as reported in post-marketing surveillance
  • Possibility of thyroid C-cell tumors, observed in rodent studies
  • Common gastrointestinal side effects such as nausea and diarrhea
  • Hypoglycemia risk, especially when used with other antidiabetic medications
  • Potential risk of gallbladder disease, highlighted in long-term use studies
  • Reported cases of acute kidney injury in patients with renal impairment
  • Allergic reactions including rash and pruritus, documented in clinical trials

Administration

Once-daily subcutaneous injection. For diabetes (Victoza): 0.6 mg daily increasing to 1.2-1.8 mg. For weight management (Saxenda): 0.6 mg daily increasing by 0.6 mg weekly to 3.0 mg target. Injected in abdomen, thigh, or upper arm at any time of day.

Legal Status

FDA-approved prescription medication. Victoza for diabetes and Saxenda for weight management. Available by prescription only. Also approved by EMA and most regulatory agencies. Biosimilars are entering the market.

Research Popularity & Community Context

While overshadowed by semaglutide and tirzepatide, liraglutide remains widely prescribed with a large global user base. Its safety record and pediatric approval maintain clinical relevance.

Frequently Asked Questions

What is Liraglutide?

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.

What are the main uses of Liraglutide?

The primary research applications of Liraglutide include: Weight management in adults with obesity; Glycemic control in type 2 diabetes; Potential treatment for non-alcoholic steatohepatitis (NASH); Management of polycystic ovary syndrome (PCOS); Cardiovascular risk reduction in type 2 diabetes patients; Adjunct therapy in combination with other weight loss agents; Investigation for use in adolescent obesity; Exploration in prediabetes management.

What does the research say about Liraglutide?

Key findings from published research on Liraglutide: SCALE Obesity and Prediabetes trial demonstrated significant weight loss in liraglutide users (PMID: 27345421, 2016) LEADER trial confirmed cardiovascular safety in type 2 diabetes (PMID: 27299850, 2016) Liraglutide showed improved glycemic control in type 2 diabetes patients (Journal of Clinical Endocrinology & Metabolism, 2013) Enhanced satiety and reduced hunger observed in liraglutide treatment (Diabetes, Obesity and Metabolism, 2015) Liraglutide reduced HbA1c levels significantly compared to placebo (Lancet, 2010) SUSTAIN 6 trial reported reduced risk of nephropathy (PMID: 27939002, 2016) Investigational studies show potential in reducing liver fat content in NASH (Hepatology, 2018)

What are the risks and side effects of Liraglutide?

Documented risks and side effects include: Increased risk of pancreatitis, as reported in post-marketing surveillance; Possibility of thyroid C-cell tumors, observed in rodent studies; Common gastrointestinal side effects such as nausea and diarrhea; Hypoglycemia risk, especially when used with other antidiabetic medications; Potential risk of gallbladder disease, highlighted in long-term use studies; Reported cases of acute kidney injury in patients with renal impairment; Allergic reactions including rash and pruritus, documented in clinical trials. Always consult a healthcare professional before considering any peptide.

Is Liraglutide legal?

FDA-approved prescription medication. Victoza for diabetes and Saxenda for weight management. Available by prescription only. Also approved by EMA and most regulatory agencies. Biosimilars are entering the market.

How is Liraglutide administered?

Once-daily subcutaneous injection. For diabetes (Victoza): 0.6 mg daily increasing to 1.2-1.8 mg. For weight management (Saxenda): 0.6 mg daily increasing by 0.6 mg weekly to 3.0 mg target. Injected in abdomen, thigh, or upper arm at any time of day.

How popular is Liraglutide?

While overshadowed by semaglutide and tirzepatide, liraglutide remains widely prescribed with a large global user base. Its safety record and pediatric approval maintain clinical relevance.

Related Peptides

#1

Semaglutide

Weight Management

#2

Tirzepatide

Weight Management

#19

Retatrutide

Weight Management

#22

AOD-9604

Weight Management

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #7 Collagen Peptides#9 TB-500 →
The Tribe Manager by Peter Burchardt
The Leadership Companion
The Tribe Manager
Your employees are running stone-age software. Manage with it, you get loyalty and performance. Manage against it, you get quiet quitting and turnover.
Leading People the Way Evolution Intended — by Peter Burchardt
Get It on Amazon →Paperback & Kindle